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Background: Metronomic chemotherapy (MC) is defined as the frequent administration
of chemotherapy at doses below the maximal tolerated dose and with no prolonged
drug-free break. MC has shown its efficacy in adult tumor types such as breast and
ovarian cancer and has to some extent been studied in pediatrics.
Objective: To assess the anti-tumor activity and toxicity of a four-drug metronomic
regimen in relapsing/refractory pediatric brain tumors (BT) with progression-free survival
(PFS) after two cycles as primary endpoint.
Methods: Patients ≥4 to 25 years of age were included with progressing BT. Treatment
consisted of an 8-week cycle of celecoxib, vinblastine, and cyclophosphamide
alternating with methotrexate. Kepner and Chang two-steps model was used with 10
patients in the first stage. If stabilization was observed in ≥2 patients, 8 additional
patients were recruited. Assessment was according WHO criteria with central radiology
review.
Results: Twenty-nine patients (27 evaluable) were included in two groups:
ependymoma (group 1, N = 8), and miscellaneous BT (group 2): 3 medulloblastoma
(MB), 5 high grade glioma (HGG), 11 low grade glioma (LGG), 2 other BT. After first
stage, recruitment for ependymoma was closed [one patient had stable disease (SD)
for 4 months]. Cohort 2 was opened for second stage since 1 HGG and 3 LGG
patients had SD after two cycles. Recruitment was limited to LGG for the second
stage and 2 partial responses (PR), 6 SD and 2 progressive disease (PD) were
observed after two cycles. Of these patients with LGG, median age was 10 years, nine
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patients received vinblastine previously. Median number of cycles was 6.8 (range: 1–12).
Treatment was interrupted in five patients for grade 3/4 toxicity.
Conclusion: This regimen is active in patients with LGG, even if patients had previously
received vinblastine. Toxicity is acceptable.
Trial Registration: This study was registered under clinicaltrials.gov – NCT01285817;
EUDRACT nr: 2010-021792-81.
Keywords: metronomic chemotherapy, pediatric oncology, angiogenesis, low grade glioma, immunity, drug
repositioning
INTRODUCTION
Despite intensive multi-modality treatment, children with brain
tumors have a variable prognosis, depending on tumor type,
quality of resection, limitations to apply radiotherapy and
resistance to chemotherapy. Most patients with relapsed brain
tumors have a dismal prognosis. Patients with low grade glioma
(LGG) may respond or stabilize to several lines of chemotherapy
and vinblastine has proven its efficacy (Bouffet et al., 2012;
Lassaletta et al., 2016). However, notwithstanding the “benign”
histology of LGG some refractory patients have a poor functional
and/or vital long term prognosis (Colin et al., 2013).
Angiogenesis is defined by the development of
neovascularization in and around solid tumors supplying
nutrients and oxygen to growing tumors. Angiogenesis plays
a key role in both tumor growth and the potential metastatic
development (Bergers and Benjamin, 2003; Ferrara and Kerbel,
2005; Kerbel, 2008). Anti-angiogenic treatments are now
established strategies to treat cancer (Colleoni et al., 2002;
Kerbel and Kamen, 2004; Kieran et al., 2005; Sterba et al.,
2006; Pasquier et al., 2007, 2010; André et al., 2008; André and
Pasquier, 2009). Metronomic chemotherapy (MC) is defined
as the frequent administration of chemotherapy at doses below
the maximal tolerated dose and without prolonged drug-free
intervals (André and Pasquier, 2009; Pasquier et al., 2010; André
et al., 2013). Metronomic therapy has a distinct mode of action
as compared to maximum tolerated dose (MTD) chemotherapy
as used in standard regimens, since it may act through various
mechanisms: by assuring continuous exposure during cell cycle,
thereby preventing tumor cell regrowth (Kerbel and Kamen,
2004; André and Pasquier, 2009; Pasquier et al., 2010); by causing
anti-angiogenic effects through affecting the tumor endothelial
cells and by targeting circulating endothelial progenitor cells
(CEP) (Ferrara and Kerbel, 2005; Pasquier et al., 2007; Kerbel,
2008; André and Pasquier, 2009), thereby contributing to tumor
dormancy; by increasing in situ drug delivery to the tumor cells
by decreasing the interstitial fluid pressure (IFP) of the tumor
environment (Pasquier et al., 2010); by restoring the anticancer
activity of the immune system by decreasing regulatory T-cells
(T-regs), or inducing dendritic cell maturation (André and
Pasquier, 2009; Pasquier et al., 2010) and by direct impact on
cancer cells or cancer stem cells (André et al., 2013, André et al.,
2017).
As a consequence MC is now regarded as a form of intrinsic
multi-targeted chemotherapy.
Metronomic chemotherapy has also been reported to
induce less severe adverse events (AEs) usually associated
with chemotherapy (Choi et al., 2008; Barber et al., 2013).
MC is frequently combined with drug repositioning or
repurposing (DR) which consists in reusing old drugs for
new indications (André et al., 2013). The combination of
MC and DR has been defined as metronomics (André et al.,
2013).
Metronomic chemotherapy has shown its efficacy in adult
tumor types such as breast and ovarian cancer (Colleoni
et al., 2002; Barber et al., 2013). The combination of anti-
angiogenic compounds such as bevacizumab with low-dose (LD)
cyclophosphamide has shown response rates as high as 42% in
refractory ovarian cancer (Barber et al., 2013).
Metronomic therapy has to some extent been studied in
pediatrics with a majority of retrospective series and phase
I or phase II trials, although randomized trials have also
been reported recently (Pramanik et al., 2017; Senerchia
et al., 2017). Combinations of thalidomide/celecoxib with
alternating LD etoposide/cyclophosphamide (Kieran et al., 2005)
showed prolonged disease stabilizations in especially CNS-
tumors. Similarly a combination of celecoxib with alternating
LD etoposide/LD-cyclophosphamide given as a maintenance
lead to sustained disease stabilization in different tumor
types (Choi et al., 2008). Continuous celecoxib and on/off
isotretinoin with alternating LD etoposide and LD temozolomide
(Sterba et al., 2006) may be beneficial in intra- and extra-
cranial tumors. Vinca-alcaloids like vinblastine may have anti-
angiogenic effects (Pasquier et al., 2007; Senerchia et al.,
2017). Vinblastine has shown its anti-tumor efficacy for the
treatment of LGG (Bouffet et al., 2012; Lassaletta et al.,
2016) and was integrated in metronomic regimens (Heng
et al., 2016), where the pharmacokinetics of combinations of
vinblastine, cyclophosphamide, and celecoxib were previously
studied. However, little is known on the anti-tumor efficacy of
this combination.
We previously reported our pilot study with a four-
drug metronomic regimen in relapsed/refractory pediatric
malignancies (André et al., 2011). This pilot led us to a
slightly modified treatment scheme with an 8 week cycle using
celecoxib, vinblastine, alternating oral cyclophosphamide, and
oral methotrexate. This MC scheme was used for a phase II
clinical trial in CNS- and non-CNS tumors. We report here the
results for the CNS tumors. The results of the other non-CNS
tumors will be reported separately.
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PATIENTS AND METHODS
Patients could be included in this multi-center, combination
phase II, open-label, non-comparative, non-randomized trial.
Thirteen pediatric oncology centers pertaining to the French
National Pediatric Oncology Society (SFCE) participated in this
phase II trial. Approval was obtained from our University Ethical
Review Board (CPP Sud Méditerranée I) and national Regulatory
Authorities [Agence Nationale de Sécurité du Medicament
(ANSM). Consent procedure was according to GCP-guidelines
with an age-adapted information and assent form and an
information and consent form for parents/guardians (in case of
minor patients).
Patients’ age was between 4 and 25 years of age and Lansky-
Play Scale should be ≥70% or ECOG Performance status ≤1.
Patients had a histologically or cytologically confirmed
malignant solid tumor (DIPG and optic pathway glioma
excluded). All progressive or recurrent solid tumors could be
included in this Phase II study, provided there were no curative
options anymore. There was no maximum in previous lines of
therapy; patients that were previously treated by vinblastine were
eligible.
Standard adequate hematological and biochemical function
were required:
– Absolute neutrophil count ≥ 1.0× 109/l
– Platelets > 75× 109/l
– Hemoglobin > 7 g/dl
– Hepatic function: AST/ALT ≤ 3 × ULN and bilirubin ≤ 2
ULN.
– Creatinine > 1.5× ULN.
Written informed consent of parent/guardian and patient
assent was collected before enrollment.
Treatment consisted of weekly vinblastine 3 mg/m2 (weeks
1 to 7), daily cyclophosphamide 30 mg/m2 (days 1–21), twice
weekly methotrexate 10 mg/m2 (days 21–42), and twice daily
celecoxib 100–200–400 mg (<20 kg BW, 20–50 kg, >50 kg,
respectively), followed by a 13 days chemotherapy break
(Figure 1).
The primary endpoint was anti-tumor efficacy as defined by
progression-free survival (PFS) after two cycles ( =8 weeks) as
assessed by conventional imaging (CT/MRI) and according to
WHO response criteria (World Health Organization, 1979).
Progressive disease (PD): 25% increase in tumor size, or
appearance of new lesions; partial response (PR): at least 50%
decrease in tumor size; complete response (CR): disappearance
of all known lesions; stable disease (SD): neither partial response
nor progression.
The secondary endpoints were:
– Progression-free survival and overall survival (OS) after
12 months of treatment.
– Response rate after any number of cycles (best response).
Central radiology review was mandatory (PD-L).
– Safety: toxicity according to NCI-CTC v3.
Adverse events were determined through laboratory analyses
and investigator observations and classified according to NCI-
CTC version 3.0.
Treatment was interrupted in case of:
Grade 3 or grade 4 non-hematological toxicity.
Grade 3 neutropenia or thrombocytopenia for more than
7 days
Grade 3 febrile neutropenia with documented infection.
Grade 4 neutropenia or thrombocytopenia.
Statistical Considerations and Feasibility
A total of 18 patients were anticipated for accrual according to
Kepner and Chang two steps model. Thus, after inclusion of the
first 10 patients, if primary objective was reached in less than 2/10
patients the cohort was closed. If primary objective was reached
FIGURE 1 | One cycle of treatment consisting of 8 weeks with four compounds.
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in two or more patients, 8 additional patients were to be recruited.
After this second stage if primary objective was reached in overall
6 patients, we concluded that the treatment is efficacious.
Ten patients were to be included in the first stage for
ependymoma (group 1) and other malignant brain tumors
(including LGG, group 2).
According to the two-step design, we defined that this regimen
is efficacious if PFS is over 34% and we considered 10% as the
limit under which this treatment is not efficacious. If alpha is 10%
and beta 10%, a maximum of 18 patients would be recruited.
Statistical analyses were done on all included subjects without
any major protocol deviations who were evaluable for primary
outcome, provided they had more than 15 days treatment. Data
are summarized for categorical variables as number of patient (%)
and continuous variables as median (range). All analyses were
summarized using descriptive statistics. Time-to-event analysis
were estimated using the Kaplan–Meier method. PFS was defined
as the time from the first treatment dose until disease progression
and global survival was defined as the time from the first
treatment dose until death from any cause. Patients who drop
out for any reason other than disease progression or death were
censored using the last contact date (we put an upper limit to
730 days). Data management and statistical analysis were done
using SAS version 9.4 (SAS Institute, Cary, NC, United States).
clinicaltrials.gov – NCT01285817; EUDRACT nr : 2010-
021792-81.
RESULTS
Patients’ Characteristics, Accrual, and
Study Duration
Enrolment lasted from January 2011 until March 2015. During
this period 29 patients were included in two groups of intention
to treat patients: 8 patients with ependymoma and 21 with
other BT. The first stage for ependymoma was not completed
because of poor enrolment. Central radiology review was
completed in November 2016, and the last follow-up analysis
was conducted in March 2017. Twenty-seven patients could be
assessed after two cycles of MC (4 months). There were 15 boys
and 12 girls. A flowchart of enrolled patients is depicted in
Figure 2.
Median age of these 27 patients was 8.5 years for the
ependymoma group and 10 for other BT. Median number of
relapses was 2.0 for the ependymoma and 3.0 for the other BT.
Fifty percent of ependymoma patients had at least two lines of
chemotherapy before inclusion whereas it was ≥3 lines in 58%
of other BT (70% for LGG). Details of the entire population and
outcomes are reported in Table 1 (characteristics) and Table 2
(treatment and outcome).
Tumor Assessment and Treatment
Duration
One patient with progressive ependymoma had SD for 4 months.
The other seven patients with ependymoma showed tumor
progression before or at the evaluation after two cycles.
FIGURE 2 | Flowchart of patients’ accrual and assessment. LGG, low grade
glioma; HGG, high grade glioma; PR, partial response; SD, stable disease;
PD, progressive disease.
For these 8 patients median number of cycles of MC
was 1.8 (0.5–3.5). Median PFS was 109 days. This cohort
was therefore not open for second stage due to lack of
efficacy.
In the cohort of other BT 12 patients were enrolled initially
since 2 patients were withdrawn because of early progression
(within 1 week; N = 1) or osteomyelitis (not-diagnosed as such at
inclusion). For this cohort, as per protocol, accrual was opened
for second stage since 1 HGG and 3 LGG patients had SD
after two cycles. The Independent Data Monitoring Committee
and the trial methodologist recommended that recruitment
should be limited to LGG for the second stage with one
supplementary patient being included. As such 21 patients were
enrolled:
– 3 medulloblastoma (MB);
– 5 high grade glioma (HGG) (2 of which DIPG);
– 11 low grade glioma (LGG);
– 2 others.
Overall, 19 “per protocol” patients could be assessed for
efficacy at cycle 2. Median PFS was 105 days. One patient with
HGG (anaplastic oligodendroglioma) stabilized for 2 years while
none of the other HGG, DIPG, or MB stabilized.
Of the 11 patients with LGG, 10 were assessable for efficacy.
Median age was 9.3 years, median duration of illness at
inclusion was 6.5 years, median number of relapses 3.5. Nine
patients previously received vinblastine, with a median duration
of previous vinblastine treatment of 4.4 months while the
median interval to previous end of vinblastine treatment was
2.5 years. One patient had neurofibromatosis type I. BRAF status
was unknown for these patients at inclusion. Two PR were
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TABLE 1 | Patients’ characteristics and previous treatment and status of disease.
Other malignant CNS tumor
Ependymoma High grade glioma Low grade glioma Other Total
(n = 8) (n = 5) (n = 10∗) (n = 4) (n = 19)
Age at inclusion 8.5 [5–13] 7.5 [4–20] 9.3 [4–15] 13.0 [11–18] 10.0 [4–20]
Sex (% of female) 1 (13%) 1 (20%) 7 (70%) 3 (75%) 11 (58%)
NF-1 status 1 (10%) 1 (5%)
Patients with metastases 1 (25%) 1 (5%)
Anterior surgery or radiotherapy
Only surgery 4 (50%) 1 (20%) 8 (80%) 2 (50%) 11 (58%)
Only radiotherapy 3 (60%) 3 (16%)
Surgery & radiotherapy 4 (50%) 1 (20%) 2 (20%) 2 (50%) 5 (26%)
Nr of previous lines of chemotherapy
0 2 (25%)
1 2 (25%) 3 (60%) 1 (25%) 4 (21%)
2 1 (13%) 1 (20%) 3 (30%) 4 (21%)
3 1 (13%) 1 (10%) 1 (5%)
>3 2 (25%) 1 (20%) 6 (60%) 3 (75%) 10 (53%)
Patients with previous vinca alkaloid 9 (90%) 2 (50%) 11 (58%)
Data are median [range] and n(%) of patients. Nr, Number. ∗Eleven patients with LGG included with one patient not assessable at two cycles.
FIGURE 3 | MRI of a patient with LGG at inclusion and after 4 months of MC.
observed, one after four cycles of MC (Figure 3), one after six
cycles.
Among the other patients 6 SD, and 2 PD were observed while
one patient was not evaluable after two cycles (Table 2). Event-
free survival at 1 and 2 years was 70% (Figure 4), while OS was
90% at 1 and 2 years. Median number of cycles was 6.8 (range:
1–12). Seven patients received at least 1 year of therapy. Nine
patients responded to the primary endpoint of having at least
disease stabilization after two cycles (4 months) of therapy. As a
consequence as per protocol we concluded that this metronomic
regimen is efficacious in the cohort of other BT, especially for
LGG.
Dose Intensity and Adverse Events
The main toxicity was hematologic and among hematologic
toxicity, neutropenia was the most common (n = 11 patients).
Grade 3/4 neutropenia occurred 21 times in 11 patients, with
4 patients (1 HGG, 3 LGG) having had 1 episode of grade
4 neutropenia. Two patients (1 ependymoma, 1 LGG) had
grade 4 febrile neutropenia. Grade 3/4 lymphopenia occurred
eight times in 5 patients, with only 1 patient with grade 4.
No grade 3/4 thrombocytopenia was observed. No grade 4
non-hematological adverse-events were observed. Hepatic
enzyme increase was the most common non-hematologic
AE (n = 8 grade 2/3). Grade 2/3 mucositis occurred in 3
patients. The other non-hematological AEs consisted of
grade 2 rhinitis/pharyngitis, fatigue, keratitis/conjunctivitis,
diarrhea, anal fissure, paraesthesia, dizziness and grade 3
hypophosphatemia and constipation. Toxicity details are
depicted in Table 3.
Treatment was interrupted temporarily in 5 patients for grade
3/4 toxicity (hepatic and/or hematological) and led to temporary
dose reductions.
The mean dose intensity of vinblastine (mean amount
of drug received and calculated over multiple cycles as a
proportion to the per protocol dose) for the 10 evaluable
patients with LGG was 90.2% after six cycles (range: 57–100%)
and 92.7% after 12 cycles (range: 75–100). One patient had
dose interruption and reduction during the first two cycles
to 50% of the intended dose because of febrile neutropenia.
The dose could ultimately be increased to 100% until the 12th
cycle. One patient had only three administrations suspended
because of herpes infection and cystitis. All the other patients
had 100% of mean dose intensity. The mean dose intensity
of cyclophosphamide for these LGG patients was 98.9% after
six cycles (range: 93–100) and 99.3% after 12 cycles (range:
96–100). The mean dose intensity of methotrexate for the
same 10 evaluable patients with LGG was 93% after six
cycles (range: 76–100) and 93% after 12 cycles (range: 69–
100) and for celecoxib the mean dose intensity was 92.0%
after six cycles (range: 67–100) and 95% after 12 cycles (range:
81–100).
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TABLE 2 | Patients’ treatment and outcome according to histology (Per Protocol population n = 27).
Other malignant CNS tumor
Ependymoma
(n = 8)
High grade glioma
(n = 5)
Low grade glioma
(n = 10∗)
Other
(n = 4)
Total
(n = 19)
Tumor status
Refractory tumors 3 (60%) 5 (50%) 1 (25%) 9 (47%)
Relapse 5 (63%) 1 (20%) 1 (25%) 2 (11%)
Refractory relapse 3 (37%) 1 (20%) 5 (50%) 2 (50%) 8 (42%)
Number of cycle of treatment received 1.8 [1.3–2.0] 0.5 [0.5–1.5] 6.8 [2.0–11.0] 1.0 [0.8–1.3] 2.0 [0.5–9.0]
Response after 2 cycles of treatment
Without progression 1 (13%) 1 (20%) 8 (80%) 9 (48%)
Progression 7 (87%) 4 (80%) 2 (20%) 4 (100%) 10 (52%)
“Best response” after any nr of cycle
CR or PR 2 (20%) 2 (10%)
Stable 1 (13%) 1 (20%) 6 (60%) 7 (37%)
Progression 7 (87%) 4 (80%) 2 (20%) 4 (100%) 10 (53%)
Median of PFS (days) 109 48 – 70.0 105
Data are median [range] and n(%) of patients. nr, number; PFS, progression-free survival. Median PFS was not attained for LGG. ∗Eleven patients with LGG included with
one patient not assessable at two cycles.
DISCUSSION
We report here the results for the two groups of children with
relapsing or refractory brain tumors included in a multicentre
phase II clinical trial using a four-drug metronomic regimen.
We developed this new multidrug metronomic regimen
for children with brain tumors and extra-cerebral tumors,
integrating the different mechanisms of action of MC. Indeed,
although MC was initially considered to be an anti-angiogenic
therapy (Bergers and Benjamin, 2003; Kerbel and Kamen, 2004;
Ferrara and Kerbel, 2005; Kerbel, 2008), recent findings have
highlighted new effects, which all likely contribute to treatment
efficacy (Pasquier et al., 2007, 2010; André and Pasquier, 2009;
André et al., 2013, 2017). These effects include the potential direct
effects against cancer cells (André et al., 2017), the stimulation of
the anticancer properties of the immune system and re-induction
of tumor dormancy (Pasquier et al., 2007, 2010; André and
Pasquier, 2009; André et al., 2013, 2017).
We designed a metronomic regimen relying mainly on
oral medications and used a continuous LD methotrexate and
cyclophosphamide backbone published in Colleoni et al. (2002).
Besides, since MC may be given for a long period of time resulting
in high accumulated doses of drugs received we wanted to avoid
etoposide and temozolomide that have been previously reported
to potentially induce secondary leukemia (Le Deley et al., 2005;
Dufour et al., 2008; André et al., 2011). Both drugs are used in
the most efficient pediatric metronomic regimen published so
far (Kieran et al., 2005; Stempak et al., 2006; Sterba et al., 2006;
Choi et al., 2008; Göbel et al., 2014; Robison et al., 2014; Ali
and El-Sayed, 2016; Berthold et al., 2017). Vinblastine was also
part of this regimen since this drug has limited hematological
toxicity and anti-tubulin agents are known to have potent anti-
angiogenic properties (Pasquier et al., 2007; Heng et al., 2016).
Moreover, vinblastine can activate dendritic cells (André and
Pasquier, 2009) and hence can be included in metronomic
protocols (Pasquier et al., 2010). Celecoxib has been part of
most pediatric metronomic regimen (Kieran et al., 2005; Sterba
et al., 2006; Pasquier et al., 2007; Choi et al., 2008; Berthold
et al., 2017) as it adds potential anti-angiogenic effects and tumor
sensitization to chemotherapy (Stempak et al., 2006) and also
display immune-modulating properties (Göbel et al., 2014).
The anti-tumor efficacy of this regimen seems predominant in
LGG where two PRs were observed and 6 SDs among 10 evaluable
patients, of which 7 patients continued treatment beyond 1 year
and 2 patients had 2 years of treatment with ongoing stabilization.
It should be emphasized that 9 out of evaluable 10 patients had
previously been treated with vinblastine, which in most patients
did not prevent a relapse or refractory disease at that time
since the median duration of previous vinblastine treatment was
only 4.4 months. Although we cannot rule out that the tumor
stabilization was caused by a re-challenge by vinblastine, it seems
likely that the addition of the other three compounds had an
additive or synergistic effect. It should be emphasized that the
patients with LGG in our series tolerated well the MC with >90%
of dose intensity of vinblastine received during the first year of
treatment but the dose of vinblastine is twice lower than the
one used by Bouffet et al. (2012). Stempak et al. (2006) reported
protracted stable disease in a patient with low grade astrocytoma
using vinblastine and celecoxib.
When comparing the observed PFS of 70% at 2 years to
other vinblastine-containing regimens for LGG, it can be noted
that this PFS is similar or even slightly better as compared to
the phase II with vinblastine monotherapy (Bouffet et al., 2012;
Lassaletta et al., 2016) where 2-year PFS was ±60%. It should be
emphasized that in this cohort of 51 patients there were 23% of
NF1 patients that responded better to vinblastine as compared to
non-NF1 patients (5-year PFS of 42%) (Lassaletta et al., 2016).
In our series only one patient had NF1. Moreover, vinblastine
was used as first line in the series as reported by Lassaletta et al.
(2016), whereas our patients with LGG in majority had had ≥3
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FIGURE 4 | Kaplan–Meier curves for overall survival (OS) and progression-free survival (PFS) of all patients with brain tumors (A), ependymoma and other brain
tumors (B), and low grade glioma separately (C).
lines of chemotherapy. It should be stressed that in the Bouffet
series 1 CR and 9 PRs were observed in 51 patients, which is a
comparable response rate as in our series (2/10 patients with a
PR). We previously reported a case-series of 4 patients with optic-
pathway glioma that received vinblastine maintenance therapy
after an induction with irinotecan and bevacizumab (IB). One
patient responded to vinblastine after being stable after IB, while
the other 3 patients remained stable, all of them having had
12 months of vinblastine therapy with a median follow-up of now
more than 30 months (Heng et al., 2016). Our results in LGG
are comparable in terms of PFS to the series of 12 LGG patients
as described by Robison et al. (2014) using a MC regimen with
continuous celecoxib, fenofibrate, thalidomide and alternating
oral etoposide with cyclophosphamide. They observed 4 PR,
5 SD, and 3 PD with however only 7 patients reaching the
27 weeks of MC where in our series 7/10 had at least 1 year
of MC. Elsewhere, Zapletalova et al. (2012) observed disease
stabilization in 9/10 low grade tumors, among which LGG,
using the COMBAT II regimen containing celecoxib, fenofibrate,
vitamin D with alternating etoposide and temozolomide. No PFS
was mentioned specifically for the patients with LGG.
The concept of MC was previously explored by several
teams in non-brain and brain tumors. Two randomized studies
were published that were performed in cohorts of pediatric
patients with relapsed extra-cranial solid tumors. Pramanik
et al. (2017) compared the effect of MC on PFS in pediatric
patients progressing after at least two lines of chemotherapy. The
MC regimen consisted of daily celecoxib and thalidomide with
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TABLE 3 | 2–4 adverse events as observed in the intention to treat population, n = 29.
Other CNS tumors
Adverse event Ependymoma
(n = 8)
High grade glioma
(n = 5)
Low grade glioma
(n = 11)
Other
(n = 5)
Total
(n = 21)
Hematologic Neutropenia 6 (75%) 2 (40%) 5 (46%) 7 (33%)
Grade 3 5 (63%) 2 (18%) 2 (10%)
Grade 4 1 (20%) 3 (27%) 4 (19%)
Lymphopenia 3 (38%) 3 (60%) 5 (46%) 1 (20%) 9 (43%)
Grade 3 2 (25%) 1 (20%) 1 (9%) 2 (10%)
Grade 4 1 (9%) 1 (5%)
Anaemia 4 (50%) 1 (20%) 4 (36%) 5 (24%)
Grade 3 1 (20%) 2 (18%) 3 (14%)
Febrile neutropenia 1 (13%) 1 (9%) 1 (5%)
Grade 4 1 (13%) 1 (9%) 1 (5%)
Non-hematologic ALAT/ASAT 1 (20%) 5 (46%) 2 (40%) 8 (38%)
Grade 3 1 (20%) 4 (36%) 2 (40%) 7 (33%)
Mucositis 1 (13%) 2 (18%) 2 (10%)
Grade 3 1 (9%) 1 (4%)
Diarrhea 1 (20%) 1 (9%) 1 (20%) 3 (14%)
Other AE 1 (13%) 2 (40%) 3 (27%) 2 (40%) 7 (33%)
Grade 3 1 (9%) 1 (20%) 2 (10%)
Data reflect n(%) of patients, referring to the predominantly observed AE (include grade 2–4). The bolded values are the cumulative frequency of grade 2–4 toxicity (as
mentioned in the legend).
alternating periods of etoposide and cyclophosphamide, whereas
the other arm received placebo. They showed no benefit on
PFS for the entire group although subgroups of patients with
none-bone sarcoma seemed to have some benefit (Pramanik
et al., 2017). Senerchia et al. (2017) showed no benefit of
72 weeks of MC containing oral daily cyclophosphamide and
twice weekly oral methotrexate after a conventional backbone of
chemotherapy for localized osteosarcoma.
Several phase II trials with MC have been published in
pediatrics (Kieran et al., 2005; Stempak et al., 2006; Sterba
et al., 2006; Pasquier et al., 2007; Choi et al., 2008; Senerchia
et al., 2017). Choi et al. (2008) used a MC regimen based on
alternating oral etoposide, temozolomide, and cyclophosphamide
in combination with either retinoic acid or celecoxib. The
patient population consisted of high risk patients with several
malignant histologies and predominantly residual disease at time
of inclusion. One PR and four prolonged SDs were observed
while 3 patients remained in remission after having no residual
disease. The responding or stabilized patients had 6–12 months
of MC (Choi et al., 2008). The responding patient had an
oligodendroglioma. In our series one patient with anaplastic
oligodendroglioma had SD for 2 years and still is progression-
free. We acknowledge the fact that these are only two cases but
may merit additional explorations given the limited therapeutic
options for these patients at relapse. Kieran et al. (2005) explored
a similar regimen with interesting responses in neuroblastoma,
LGG, malignant fibrous histiocytoma, and medulloblastoma.
In our phase II clinical trial, no significant activity was
observed in other brain tumor histologies but LGG. Nearly
all patients with HGG (one excluded), ependymoma,
medulloblastoma, or other BT were not stabilized by our
regimen. This is in contrast with the series reported by Kieran
et al. (2005) where prolonged remissions/stabilizations were
observed in ependymoma (n = 4/5), medulloblastoma (n = 1/1)
and optic pathway glioma (n = 1/1), after using a metronomic
regimen with thalidomide, celecoxib and alternating etoposide
and cyclophosphamide (Kieran et al., 2005). In the 19 patients
with ependymoma reported by Robison et al. (2014), 2 PR,
10 SD, and 7 PD were observed with 37% having at least
27 weeks of MC. These observations were one of the rationale to
explore a separate group of ependymoma in our phase II trial.
The MC regimen consisted of alternating oral etoposide and
cyclophosphamide with continuous thalidomide and celecoxib.
We can consider that the lack of etoposide and/or temozolomide
in our MC regimen led to an inadequate efficacy in our groups of
BT (LGG excluded).
We want to emphasize that even if MC is considered to induce
lower toxicity, that our series showed acceptable though notable
AEs with a majority of grade 2 or 3 events and few grade 4 events.
We had more grade 3/4 hematologic toxicity as compared to the
series published by Ali and El-Sayed (2016) who used a similar
MC scheme in combination with focal RT. A high clinical benefit
rate of 76% was observed with only grade I hematological toxicity
observed. It should be emphasized that pathologies and previous
treatments were not comparable to our series.
CONCLUSION
The four-drug regimen we report on here was rather well-
tolerated and showed anti-tumor activity in relapsed LGG, even
in patients having had previously received vinblastine treatment.
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These results warrant additional explorations in larger patients’
series while comparing to vinblastine mono-therapy.
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